Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Durasphere Post-Approval Studies Should Focus On Subgroups - FDA Panel

This article was originally published in The Gray Sheet

Executive Summary

Advanced UroScience is anticipating a worldwide launch of the injectable bulking agent Durasphere sometime in the fourth quarter, following an approvable recommendation from FDA's Gastroenterology and Urology Devices Panel at its July 29 meeting in Rockville, Maryland.

You may also be interested in...

Advanced UroScience Durasphere Post-Approval Study Focuses On Durability

Advanced UroScience's post-approval study of its Durasphere bulking agent for treatment of female stress urinary incontinence due to intrinsic sphincter deficiency will focus on evaluating the durability of the product, the company reports.

Colgate Prioritizes Growing Brands Over Adding More; Increasing Costs Drive Prices Higher

Colgate is “not in a hurry” to make deals with valuations high for businesses it would target, says CEO Noel Wallace. Increasing commodity costs and rising inflation have the company prioritizing growth on existing businesses.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts